Avolynt is a clinical stage drug development company based in Research Triangle Park, North Carolina. The Company's mission is to improve the lives of patients suffering from dysfunctions related to human metabolism. Avolynt's team has significant discovery and development experience across the metabolic syndrome, including metabolic related rare disease, diabetes, obesity, and nonalcoholic steatohepatitis (NASH). The Company has two marked products in India and its lead development program is in Phase 2.